Envision Pharma Group announces appointment of Dr. Deepti Sodhi Jaggi to Board of Directors

Envision Pharma Group (Envision) has appointed Dr. Deepti Sodhi Jaggi to the Envision Board of Directors

“We are pleased to welcome Deepti to the Envision Board of Directors,” shares Meg Heim, CEO of Envision Pharma Group. “Deepti’s deep experience in the technology of Artificial Intelligence (AI) and digital therapeutics in the life sciences industry will be invaluable to our mission at Envision as we continue to accelerate our global business expansion and commitment to our clients, and most importantly, impacting patient lives in a positive manner.” 

Dr. Jaggi’s career includes over 20 years of experience in driving innovation at the intersection of life sciences, healthcare, and technology. Her expertise is in transforming businesses through software, AI/ML, and advanced analytics. Most recently, she served as Chief Strategy & Commercial Officer at Better Therapeutics, a publicly held digital therapeutics company. Before that, she served as the Global Head of Patient Insights & Solutions at Astellas Pharmaceuticals with responsibility for the Americas, EMEA, China, and Japan.

Prior to that, Dr. Jaggi served as President & Chief Medical Officer at Clinakos Inc., a Silicon Valley company at the forefront of leveraging data and AI in healthcare and life sciences. She helped grow Clinakos from startup to revenue stage, serving multiple top pharmaceutical companies.

Dr. Jaggi’s previous experience includes positions of increasing responsibility and leadership at Johnson & Johnson, Genentech, Oracle, and Kaiser Permanente. She has also served as a consultant to TPG Capital and is a member of the Board of Directors for Technology Credit Union in the San Francisco Bay Area.

“I am thrilled to join the Envision Board at such an exciting time for our industry. I look forward to working with an immensely talented team to accelerate innovation in life sciences through technology and scientific solutions to positively impact patient lives,” says Dr. Jaggi. 

Dr. Jaggi’s educational background includes a PharmD from the University of Southern California and an MBA from Stanford Graduate School of Business. 

Close

Leading global technology-enabled scientific communications company Envision Pharma Group has promoted Paul Archer to Chief Commercial Strategy Officer (CCSO).

In his new role, Archer will lead the development of an integrated commercial group strategy to drive continued revenue growth through service synergies and the implementation of new services. This is a newly defined position that reflects the continued expansion of Envision and its goals of being the global medical affairs partner of choice and to transform the pharma industry, ultimately leading to life-changing outcomes.

Working across the group, Archer will leverage Envision’s unique combination of technology and service capabilities to meet the evolving needs of its medical affairs clients and ensure it continues to lead the way in bringing innovative solutions to the market.

On his appointment that also sees Archer join Envision’s Executive Leadership Team, he said, “I am thrilled to be taking on this role. Envision is full of purpose-driven, talented people who thrive on delivering impactful, often award-winning work for our clients and their patients. I am genuinely excited to be able to apply my 20 years of strategic and commercial experience to drive a successful integrated commercial group for Envision and to realize the opportunities and value this creates for our clients, patients, talent, and Envision as a whole.”

David Thompson, CEO, Envision Pharma Group, added, “Paul has been a strong addition to Envision since he joined a year ago, and he will now lead a growing mandate as Chief Commercial Strategy Officer as we continue to exploit synergies across our four verticals of scientific services, technology, emerging biotech, and value – as well as uncover new service offerings through investment and acquisition that can help us improve our partnership strength with clients.”

Close

Leading global technology-enabled scientific communications company Envision Pharma Group has appointed Julie Beeso as its Global Director, Professional Development and Engagement.

Having worked for almost 25 years across different medical communications roles in the UK and US, Julie’s extensive expertise will be used to develop, communicate, and execute a comprehensive professional development and talent management strategy for Envision Scientific Solutions (ESS) that supports progressive programs and engagement.

Starting out as a writer, Julie advanced to facilitating the account direction and team leadership for blockbuster launches in a previous role; overseeing new business activities; heading up a company division, and establishing a New York office. Julie joins Envision from Oxford PharmaGenesis where she helped to set up and lead its patient engagement specialty while also focusing on company-wide quality and training activities.

Alongside continuing to teach people how to be the best they can be in a competitive medcomms landscape, Julie’s responsibilities will cover ESS engagement and relations, talent placement and retention, alternative resourcing, and overseeing performance management.

Julie said, “I feel privileged to have the opportunity to work for Envision, whose reputation for integrity and quality – always alongside technological innovation – is second to none. Envision excels through its talented people. The company’s commitment to developing this talent is dynamic and inspiring, and I can’t wait to help take it to the next level!”

Susanne Clark, Global Head, Envision Scientific Services added, “We are thrilled to have Julie Beeso joining the team. With deep market insight and a unique skill set, Julie is ideally placed to meet the needs of a complex and rapidly evolving talent market. At Envision we have grown through continual innovation and improvement, and Julie will begin by scaling up our successful New Medical Writer program and elevating our entry talent offering. We are excited by this new chapter in our talent story.”

Close

Global healthcare communications consultancy 90TEN, part of Envision Pharma Group, today announced its expansion to the US market and appointment of Kate Paxton as its US Head.

Paxton will oversee projects with a number of current 90TEN and Envision Pharma Group clients, grow her US team of healthcare communications specialists, leverage the existing rich resources within the organization for US client needs, and showcase the agency and its unique culture and approach.

“We are thrilled to have such an experienced and passionate professional like Kate join the growing 90TEN team,” said David Thompson, Chief Executive Officer, Envision Pharma Group. “Kate’s long history of building strategic and creative programs for healthcare clients of every size and scope – in addition to her deep understanding of how agencies grow and thrive – makes her ideally suited to lead 90TEN through this next, exciting phase.”

Paxton has almost 30 years of experience in agency communications and healthcare, ranging from corporate communications, product comms, and advocacy relations – to celebrity campaigns and issues management. Prior to 90TEN, Paxton spent a year and a half at JPA Health, where she designed and led campaigns for several biotech companies focused on oncology and rare diseases, and almost 23 years at Ketchum, where she held multiple leadership positions, including Managing Director of London Health for over 2 years and Practice Director of Washington, D.C. Health for over 7 years.

Campaigns that Paxton led have won multiple industry awards, including three Silver Anvils from the Public Relations Society of America and one Healthcare Campaign of the Year from PR Week.

“I have been an admirer of 90TEN for many years and always respected how bold, creative, and effective their campaigns are,” Paxton said. “So, when the opportunity came to lead the US launch and rollout, maximize the incredible talent and resources that already exist, and work with the award-winning London team – all of whom are passionate about changing lives for the better – I jumped at the chance.”

Based in London, 90TEN is one of the leading healthcare communications consultancies in Europe and works with half of the top 20 pharma companies in the world serving clients across Europe and North America. In 2020, it was named Communications Consultancy of the Year at both the Communiqué Awards and Sabre EMEA Awards. That same year, it became part of Envision Pharma Group – a global provider of evidence-based communication services and industry-leading technology solutions.

Thompson added, “The US PR marketplace is highly competitive, but given the pairing of Envision’s footprint and deep scientific capabilities with 90TEN’s award-winning, behavioral science approach, we are confident that 90TEN US represents an exciting new offering for the American market.”

Close

Two Labs, an industry-leading pharma services company and part of Envision Pharma Group, today announced that it has acquired Riparian, a pharma consulting and SaaS company that helps manufacturers navigate pricing regulations, reporting, strategies, and program operations.

The acquisition expands Two Labs’ suite of pharma services, allowing the company to provide greater insights around the financials associated with launching and managing a drug, better positioning manufacturers for long-term success. Riparian’s deep understanding of government pricing regulations and program operations – combined with their consulting, business process outsourcing, and software capabilities – enables clients to better understand the financials of their drug, ensuring the prices reported to the government are in compliance with current government statutes and regulations.

“Government regulations and reporting requirements are growing increasingly complicated and it’s vital for both emerging and established manufacturers to work with an expert partner during this process,” said Howard Miller, CEO, Two Labs. “Riparian is a quickly growing, innovative company backed by a team of leading industry experts. It’s a privilege to have been selected as their partner by their leadership team.”

Riparian and Two Labs will work together to accelerate parent company, Envision Pharma Group’s US expansion plans in the emerging biotech pharma market. Envision acquired Two Labs in November 2020.

“This acquisition solidifies our vision to add Two Labs to the Envision family,” said David Thompson, CEO of Envision Pharma Group. “Bringing together Two Labs and Riparian reinforces Envision’s mission to invest in truly transformative organizations, and further expands our capabilities in improving patient access to life-changing medicines.”

“Like Two Labs, we’re committed to staying at the forefront of the evolving healthcare market, and we are excited for the growth we can experience by incorporating additional services and subject-matter expertise to meet evolving client needs,” said Riparian Co-Founder and CEO, David Chan. “This partnership elevates the work of both Two Labs and Riparian and creates significant growth potential.”

Riparian will continue operating out of their existing headquarters in Henderson, NV, with offices in Pasadena, CA and Johnson City, TN. Co-founders David Chan and Cynthia Hwang will remain with the company.

Close

Envision Pharma Group (“Envision” or the “Company”), a leading global technology-enabled scientific communications company, is pleased to announce the acquisition of doDOC Corp., a leader in document collaborative review, editing, and authoring.

doDOC is an innovative, best-in-class, Software as a Service (SaaS)-based platform that enables simultaneous collaboration in the review, editing, and authoring of documents among multiple users. Designed for the pharma and life sciences industries, it offers significant industry-specific advantages over general document authoring solutions in the market today.

While customers will have the choice to deploy doDOC standalone, the solution will be seamlessly integrated with Envision’s leading medical affairs platform, iEnvision. This unlocks the huge potential for customers to allow real time in-line editing of medical affairs documents, delivering efficiency gains of around 70% versus document processes without doDOC.

Founded in 2015 in Boston, MA, with a European base in Coimbra, Portugal, the company will operate as a business unit under its current brand and will continue to be led by doDOC CEO and co-founder, Federico Cismondi.

David Thompson, CEO, Envision, said, “Bringing doDOC into the Envision family enables us to continue to increase our innovative technology offerings to support life science companies’ goals in becoming ever more efficient and effective in the communication of key scientific data. doDOC is the standout company in its field and, critically, shares our values and commitment to working collaboratively to provide smart solutions that ensure our clients’ success. It will also allow us to consider developing capabilities that enable us to spread beyond our medical affairs client base, including supporting client commercial activities.”

“Envision’s acquisition of doDOC is great for our customers and employees. It allows doDOC to join a proven medical affairs technology leader and advance our solutions for the industry,” said Federico Cismondi, CEO, doDOC. “Most importantly, our companies share a commitment to provide industry-leading innovate solutions and to work together in a collaborative way to ensure our customers’ success.”

Manish Goel, Global Head of Envision Technology Solutions, added, “With our first clients now live on an integrated doDOC and iEnvision platform, we have a capability that no one else in the market can credibly claim as part of their solution. With doDOC as part of Envision Pharma Group, we can broaden our technology capabilities, creating efficiencies for clients and adding value as a strategic partner to deepen our client relationships.”

Close

Envision Pharma Group (“Envision” or the “Company”), a leading global technology-enabled scientific communications company, is pleased to announce the acquisition of Two Labs, an industry-leading provider of integrated and customized commercial solutions to the pharmaceutical and biotechnology sector.

• Two Labs brings market-leading commercialization, strategic consulting, market access, and market intelligence solutions that span the full product life cycle
• Move builds on Envision’s established leadership position as the preferred tech-enabled scientific communications company for medical affairs, while deepening its presence in the critical US domestic market, and with small and midsize biopharma clients
• Group to deliver customized “launch excellence” offering, becoming a global go-to strategic partner for pharma in medical affairs, healthcare communications, and consulting services –charting the path from clinical to commercial for a new product, and guiding clients on the optimum journey

The combined company will bring together complementary clients, services, and technologies, extending Envision’s scientific footprint to new clients in the “product pre-launch setting” – while opening up new business avenues and geographies for Two Lab’s best-in-class launch planning services.

Two Labs, founded in 2003 and headquartered in Powell, Ohio, has offices and operations across the US and UK, and is an established strategic consulting and commercialization provider to the biopharma industry. Two Labs helps pharmaceutical companies develop and execute customized launch strategies for products. It has a proven track record of successful launches across all major therapeutic areas with unmatched client satisfaction.

Envision’s acquisition of Two Labs follows the recent announcement of GHO Capital’s increased investment in the company and the backing of management for its continued global expansion. Since being founded in 2001, Envision has delivered strong year-on-year organic growth and established leadership in medical affairs strategy, medical communications, and enterprise-wide iEnvision® technology. A number of strategic acquisitions in medical strategy, Health Economics and Market Access (HEMA), and behavioral science-led communications have played an important role in its expansion.

David Thompson, CEO, Envision, said, “This exciting combination of Envision and Two Labs creates a compelling and unrivaled proposition in launch excellence partnership globally and in the US. We look forward to sharing our joint expertise and leveraging our complementary services across medical affairs and product launch planning to support our clients in their goal of bringing new medicines to market effectively and compliantly, to improve patient outcomes.”

Howard Miller, CEO, Two Labs, added, “We are delighted to be joining the Envision family and taking Two Labs to the next logical step in its successful journey to date. With Envision’s global footprint and Two Labs’ market-leading US footprint, we have a unique opportunity to enrich our client partnerships with more connected services across the launch continuum. The cultural fit between our organizations is compelling, and we look forward to a new chapter for Two Labs in partnering with David and the Envision team.”

The Partners at GHO commented, “We are glad to welcome Howard and the Two Labs team to the Envision Group. They have built a market-leading strategic consulting and commercialization business that in combination with Envision’s position as the ‘go-to’ tech-enabled scientific communications company will deliver major value to global pharma and biotech through a combined, unique launch excellence offering that accelerates and improves their route to market.”

Excellere Partners, a US-based private equity firm focused on partnering with entrepreneurs and management teams in emerging growth companies, will exit its investment in Two Labs following a successful 4-year partnership.

Close

Global Healthcare Opportunities, or GHO Capital Partners LLP, the European specialist investor in healthcare, together with the existing Envision management team and employees, have increased their investment in Envision Pharma Group (“Envision” or the “Company”), a leading technology-enabled scientific communications company.

The transaction sees GHO lead a consortium of its investors headed by Mubadala Investment Company, and including HarbourVest Partners and Northwestern Mutual to drive a new phase of growth, while Ardian exits its investment following a successful 4-year partnership with Envision and GHO.

Founded in 2001, Envision helps biopharmaceutical and medical device companies commercialize new compounds through medical strategy, strategic publications planning, and medical communications delivery. Its flagship technology iEnvision^® – a global medical affairs platform, supports medical strategy, scientific communications internal/external research, and grant/request management activities to help pharmaceutical companies operate their businesses compliantly.

Over the last 19 years Envision has enjoyed outstanding year-on-year organic growth, with expansion supplemented via a number of key strategic acquisitions in medical strategy, Health Economics and Market Access (HEMA), and behavioral science-led communications. Consequently, Envision’s global reach now extends to Australia, Japan, Serbia, and Hungary, with the company employing over 800 people across 14 offices.

Having partnered with Envision for 4 years, GHO has a unique view of the business and its growth trajectory and is backing the management for continued expansion. Envision will pursue significant rollout of its iEnvision technology to widen its suite of platform solutions and strategic communications capabilities, and expects to see increased synergy between these two elements.

With acquisitions likely to play an important role toward facilitating the delivery of a deeper, more diversified service offering to global clients, Envision is set to enhance its position as the leading strategic medical affairs partner to the pharmaceutical industry.

David Thompson, CEO, Envision, said, “Having worked alongside GHO for 4 years, we are delighted they have chosen to extend and deepen the partnership in a new investment cycle. We see a clear commitment to expanding our reach across the healthcare services spectrum, most notably in medical affairs, with the ultimate goal of enhancing physicians’ abilities to improve patient outcomes.”

The Partners at GHO Capital commented, “We are delighted to continue our successful partnership with David and his management team. Envision is a company we know well and continue to believe in owing to its unique services and technology proposition. We look forward to supporting this ambitious team on their next phase of growth and in delivering Envision’s full potential as the go-to strategic partner in outsourced medical affairs, communications, and consulting services.”

Brian Hepburn, Co-Chairman and Founder, Envision, added, “For GHO Capital to take the majority shareholding in Envision speaks volumes in terms of its belief in our business and vision. We will be partnering with a team who already has a deep understanding of both the healthcare sector and our business, who know and respect the leadership team, and can positively contribute to our new 5-year business plan.”

Bruno Ladriere, Managing Director of Ardian Buyout in the UK, said, “Over the last 4 years, we have worked successfully with the Envision management and GHO to support the company’s growth, adding new service lines via acquisitions to increase the value brought to its clients. This first investment of our Buyout team in the UK has been a great success. We are confident the next phase of the Envision story will continue to demonstrate the company’s standing as the trusted partner of choice for medical affairs to the pharmaceutical industry.”

Close

The PM Society Digital Awards 2020 saw Envision pick up two Silver awards for Congress, Meetings & Events and for Innovation – Creativity as a result of its “See through diabetes” work in collaboration with Mundipharma.

Multichannel Director at Envision, Alex Watson, said, “These two Silver awards are another fantastic accolade for Envision. Following our success at the PM Society Awards in 2019, this really is testament to the excellence and consistency that our creative/digital team achieve. Congratulations to our exceptionally talented team that, in close partnership with Mundipharma and supported by Woolley Pau, conceptualized this novel and impactful way to engage a larger audience with this important and valuable message.”

Nick Morgan, Head of Specialist Driven Primary Care, Europe, Mundipharma, added, “We are thrilled that Mundipharma has been recognized for digital excellence in communicating this important message that will help to positively impact the lives of Type 2 Diabetes (T2D) patients everywhere. We put healthcare professionals and the patients they serve at the heart of everything we do, and to be recognized at the PM Society Digital Awards for this project is testament to this. Working with the Envision team to achieve these goals is a true partnership, where our objectives and vision meet the creativity and know-how to produce these exceptional results.”

2020 marks the eleventh year of the PM Society Digital Awards, where the best in digital creativity, innovation, and effectiveness are recognized from across the healthcare industry. The event prides itself on highlighting the best programs, tools, and campaigns across a broad range of digital activities.

Watson also noted, “Digital excellence is not just about employing the latest technology, but ensuring technological solutions support the creative proposition and aid in achieving the core communication objectives.”

Close

Global healthcare communications consultancy 90TEN, part of the Envision Pharma Group, was last night named Healthcare PR Consultancy of the Year at the SABRE Awards EMEA 2020.

Commenting on the award win, Paul Tanner, Global Head, 90TEN said, “2019 was 90TEN’s most successful year to date, driven by further investment in our team and the continued adoption of the company’s behavioral science-led communications services by clients. It’s terrific to see our ongoing expansion and to receive recognition for this across the EMEA region. This award is a reflection of the dedication of our incredible team and clients, who are passionate about making a difference through life-changing work.”

The consultancy was also a finalist for the Best Digital Campaign category for its “HIV Garage” program for Gilead Sciences.

The SABRE Awards are the world’s largest PR awards program, recognizing superior achievement in branding and reputation in North America, EMEA, Asia-Pacific, Latin America, South Asia, and Africa. The awards are delivered by PRovoke Media, the authoritative voice of the global public relations industry.

Close

90TEN, part of Envision Pharma Group, was honored to be named Communications Consultancy of the Year at the 2020 Communiqué virtual awards ceremony last night. The consultancy also received a high commendation in the Young Achiever in Healthcare Communications category for 90TEN’s Rebecca Tait.

“We are extremely proud to celebrate this award win. To be recognized as Communications Consultancy of the Year for the second year in a row is an incredible achievement. This award is testament to the life-changing work of our passionate and talented team,” said Paul Tanner, 90TEN’s Global Head. “Looking ahead, we are bolstering our global footprint and service offering through our partnership with the Envision Pharma Group so that we can bring our life-changing work to more people around the world.”

Communiqué judges said that, “90TEN came out on top after a stellar year, staying true to itself as a business whilst diversifying, with some superb results to show for it. The judges were particularly impressed by 90TEN’s strong internal culture that drives its success, how business development is broadened through working closely with clients, and use of employee sickness as a powerful measure of a healthy working environment.”

The Communiqué Awards recognize and reward outstanding work in healthcare communications both in the UK and internationally, and are judged by a panel of industry experts and leaders. This year, 90TEN was shortlisted for six awards including Medical Affairs Agency and Communications Consultancy of the Year, Excellence in Healthcare Partnerships and Multichannel Communications, as well as individual awards for Healthcare Communications Leader, and Young Achiever in Healthcare Communications.

Close

Envision has achieved sixth position in the annual ranking of the UK’s Top 50 fastest-growing privately owned pharma businesses.

This marks the second successive year Envision has reached financial services firm Alantra’s Pharma Fast 50 list. Based on revenue growth, it recognizes the key British companies that are driving the healthcare sector forward.

Envision CEO David Thompson said, “We are very proud to be named once again in the Pharma Fast 50 list. To move from 19th place in 2019 to sixth in the rankings this year, speaks to all the hard work and dedication our superb team has put in as we continue to expand our technology-enabled scientific services for clients.”

Alantra Director and report author Tom Cowap comments in the publication, “These are dynamic and innovative businesses that continue to deliver remarkable growth and we are proud to highlight their success.”

Aside from additional recent industry awards that have been based on client campaigns and innovation within the sector, Envision as a business has previously enjoyed year-on-year accolades:

2019 – Positioned 19th in Alantra Pharma Fast 50, fastest-growing privately owned pharma business

2018 – Awarded at Super Sussex Growth event that highlighted top-performing, job-generating businesses

2017 – Named Best in Business for sustained sales growth as a mid-market company among the Top 20 fastest-growing businesses

To view the 2020 Pharma Fast 50 report, click here.

Close